PolyPid (NASDAQ:PYPD) Price Target Cut to $11.00 by Analysts at HC Wainwright

PolyPid (NASDAQ:PYPD) had its price target dropped by HC Wainwright from $14.00 to $11.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 280.62% from the company’s previous close.

Separately, Craig Hallum began coverage on PolyPid in a research note on Monday, November 4th. They set a “buy” rating and a $10.00 price objective on the stock.

PolyPid Stock Up 1.4 %

Shares of PolyPid stock opened at $2.89 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. The business has a 50-day moving average price of $3.24 and a 200 day moving average price of $3.52. PolyPid has a fifty-two week low of $2.37 and a fifty-two week high of $9.20. The firm has a market cap of $13.86 million, a P/E ratio of -0.37 and a beta of 1.33.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC bought a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid as of its most recent SEC filing. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.